Clinical practice trends and therapeutic preferences in osteoarthritis management: a cross-sectional survey of orthopaedic surgeons in India

Manish Khanna; Amitava Narayan Mukherjee; Partha Sarathi Sarkar; Vishnu Senthil; Rajesh Gupta; Shantanu Lakhar; Atul Sharma; Tanya Bhagat

doi:10.18203/issn.2455-4510.IntJResOrthop20253417

Authors

Manish Khanna Department of Orthopaedics, Dr. KNS Memorial Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Amitava Narayan Mukherjee Indian Orthopaedic Rheumatology Association
Partha Sarathi Sarkar Department of Orthopaedics, North Bengal Medical College & Hospital, Kolkata, West Bengal, India
Vishnu Senthil Department of Orthopaedics, Government Royapettah Hospital, Chennai, Tamil Nadu, India
Rajesh Gupta Department of Orthopaedics, ASCOMS and Hospital, Jammu, Jammu and Kashmir, India
Shantanu Lakhar Department of Orthopaedics, Archana Trauma and Orthopedics Hospital, Dibrugarh, Assam, India
Atul Sharma Medical and Scientific Affairs, GSK Consumer Healthcare/Haleon, Gurugram, Haryana, India
Tanya Bhagat Medical and Scientific Affairs, GSK Consumer Healthcare/Haleon, Gurugram, Haryana, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20253417

Keywords:

Osteoarthritis, Nonsteroidal anti-inflammatory drugs, Intra-articular injections, Nutraceuticals, Undenatured type II collagen

Abstract

Background: Osteoarthritis (OA) is a leading cause of disability worldwide and presents a growing challenge, particularly in India’s aging population. Despite its burden, there is a limited data exist on how OA is managed in real-world clinical settings across India. This study assessed the prescribing patterns and therapeutic preferences of orthopaedic surgeons in India, focusing on pharmacological interventions, intra-articular therapies, and the utilization of adjunctive treatments such as collagen and nutritional supplements.

Methods: A total of 250 orthopaedic surgeons across India participated in this cross-sectional survey carried out by the Indian Orthopaedic Rheumatology Association (IORA). The 32-item questionnaire created by orthopaedic surgeons explored clinical observations, treatment preferences, comorbidity challenges, and attitudes toward nutraceutical use in OA management.

Results: Most clinicians reported a high OA burden in their practice, with symptom onset frequently observed as early as 30–45 years. Obesity and poor nutritional status were identified as common complicating factors. Lifestyle modification was the preferred initial approach, followed by acetaminophen as the first-line pharmacologic agent, especially in elderly patients or those with comorbidities. Topical NSAIDs were favoured for their efficacy and safety profile. A growing role for undenatured collagen type II (UC-II, Lonza) was evident, with 55.2% of respondents prescribing it routinely, particularly in mild-to-moderate OA. Over 75% supported its early initiation, and nearly half considered it for preventive use in high-risk individuals.

Conclusions: Indian orthopaedic surgeons are increasingly adopting a holistic, multimodal approach for osteoarthritis management, balancing early intervention with safety. The growing use of UC-II and nutritional supplements highlights a preventive shift in clinical practice.

Metrics

Metrics Loading ...

References

Desai H, Shah R, Shah H, Thakkar K. Prevalence and medicinal practices for osteoarthritis in Western India. Natl J Physiol Pharmacy Pharmacol 2020;11:78-83. DOI: https://doi.org/10.5455/njppp.2021.11.10289202006112020

Osteoarthritis. Who.int. Available at https://www.who.int/news-room/fact-sheets/detail/ osteoarthritis. Accessed on 12 April 2025.

Xie X, Zhang K, Li Y, Li Y, Li X, Lin Y, et al. Global, regional, and national burden of osteoarthritis from 1990 to 2021 and projections to 2035: A cross-sectional study for the Global Burden of Disease Study 2021. PLoS One 2025;20(5):e0324296. DOI: https://doi.org/10.1371/journal.pone.0324296

Singh A, Das S, Chopra A, Danda D, Paul BJ, March L, et al. Burden of osteoarthritis in India and its states, 1990-2019: Findings from the Global Burden of disease study 2019. Osteoarthritis Cartilage. 2022;30:1070-8. DOI: https://doi.org/10.1016/j.joca.2022.05.004

Siddiqui RA, Shende TR, Salankar HV, Rode SB. Drug prescription pattern in osteoarthritis in a tertiary care teaching hospital. J Pharm Res Int. 2022;34(6):19-24. DOI: https://doi.org/10.9734/jpri/2022/v34i6A35427

Gupta R, Malhotra A, Malhotra P. Study of prescription pattern of drugs used in the treatment of osteoarthritis in a tertiary care teaching hospital: An observational study. Int J Res Med Sci. 2018;6:985-9. DOI: https://doi.org/10.18203/2320-6012.ijrms20180627

Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016;4:CD007400. DOI: https://doi.org/10.1002/14651858.CD007400.pub3

Bishnoi M, Kumar A, Kulkarni SK. Prescription monitoring of management pattern of osteoarthritis with non-steroidal anti-inflammatory drugs at PUHC, Chandigarh in India. Indian J Pharm Sci. 2006;68:525-7. DOI: https://doi.org/10.4103/0250-474X.27837

Ullal DS, Narendranath S, Kamath KR, Pai SM, Kamath US, Savur AD. Prescribing pattern for osteoarthritis in a tertiary care hospital. J Clin Diagn Res. 2010;4:2421-6.

Jhanwar P. Drug utilization study of osteoarthritis in a tertiary care teaching hospital of Rajasthan. Int J Pharm Scie Rev Res. 2012;14:35-7.

Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, et al. An up to date on clinical prospects and management of osteoarthritis. Ann Med Surg. 2021;72:103077. DOI: https://doi.org/10.1016/j.amsu.2021.103077

Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O. Recent advances in the management of knee osteoarthritis: A narrative review. Front Med (Lausanne). 2025;12:1523027. DOI: https://doi.org/10.3389/fmed.2025.1523027

Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023;31:458-66. DOI: https://doi.org/10.1016/j.joca.2022.11.005

Staff U. Nutraceutical treatment in knee osteoarthritis. Open J Orthop. 2022;12:303-26. DOI: https://doi.org/10.4236/ojo.2022.127030

Zhou Y, Zhang Y, Dai H, Zhang Y, Fu Y. The potential of undenatured type II collagen against arthritis: a review. Collagen Leather. 2024;6(1):17. DOI: https://doi.org/10.1186/s42825-024-00160-y

Luo C, Su W, Song Y, Srivastava S. Efficacy and safety of native type II collagen in modulating knee osteoarthritis symptoms: A randomised, double blind, placebo-controlled trial. J Exp Orthop. 2022;9(1):123. DOI: https://doi.org/10.1186/s40634-022-00559-8

Yatish DR, Naveenkumar D, Bilagi DA, Joshi D. Evaluation of clinical efficacy of undenatured type ii collagen in the treatment of osteoarthritis of knee. A randomized controlled study. Int J Orthop Sci. 2020;6(2):497-500. DOI: https://doi.org/10.22271/ortho.2020.v6.i2h.2089

Mehra A, Anand P, Borate M, Paul P, Kamble S, Mehta KD, et al. A non-interventional, prospective, multicentric real life Indian study to assess safety and effectiveness of un-denatured type 2 collagen in management of osteoarthritis. Int J Res Orthop. 2019;5:315-20. DOI: https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20190798

Saini N, Rawat S, Saresa H, Mehta KD, Jain R. A cross-sectional survey of orthopaedicians to understand the prescribing pattern of disease modifying osteoarthritis drugs in osteoarthritis. Int J res Orthop. 2019;5:670-4. DOI: https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20192682